CX Institutional Purchases Shares of 522 Novo Nordisk A/S (NYSE:NVO)

CX Institutional acquired a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 522 shares of the company’s stock, valued at approximately $36,000.

Other large investors have also modified their holdings of the company. Sanibel Captiva Trust Company Inc. boosted its stake in Novo Nordisk A/S by 9.4% in the first quarter. Sanibel Captiva Trust Company Inc. now owns 17,026 shares of the company’s stock valued at $1,182,000 after acquiring an additional 1,458 shares in the last quarter. SG Americas Securities LLC increased its position in Novo Nordisk A/S by 5.5% during the first quarter. SG Americas Securities LLC now owns 113,673 shares of the company’s stock worth $7,893,000 after buying an additional 5,948 shares during the period. Dividend Assets Capital LLC grew its position in shares of Novo Nordisk A/S by 24.0% during the first quarter. Dividend Assets Capital LLC now owns 266,187 shares of the company’s stock worth $18,484,000 after acquiring an additional 51,572 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Novo Nordisk A/S by 9.6% in the 1st quarter. GAMMA Investing LLC now owns 9,466 shares of the company’s stock valued at $657,000 after acquiring an additional 827 shares during the period. Finally, Fourpath Capital Management LLC boosted its stake in Novo Nordisk A/S by 10.5% during the 1st quarter. Fourpath Capital Management LLC now owns 3,652 shares of the company’s stock worth $254,000 after purchasing an additional 346 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 3.4%

Shares of NVO opened at $74.38 on Wednesday. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $148.15. The stock’s 50-day moving average is $67.80 and its two-hundred day moving average is $79.21. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The firm had revenue of $11.87 billion for the quarter. On average, research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NVO has been the subject of several recent research reports. BMO Capital Markets reiterated a “market perform” rating and set a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Hsbc Global Res raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, April 28th. Wall Street Zen raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Saturday. BNP Paribas assumed coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an “underperform” rating on the stock. Finally, Dbs Bank downgraded shares of Novo Nordisk A/S to a “sell” rating in a report on Friday, April 25th. Two analysts have rated the stock with a sell rating, five have given a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $112.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.